LOAMU
OVID icon

Lombard Odier Asset Management (USA)’s Ovid Therapeutics OVID Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-31,250
Closed -$328K – 243
2017
Q2 		$328K Buy
+31,250
New +$408K 0.03% 232

Other funds holding OVID

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s OVID Position: Q3 2017 in Review

Lombard Odier Asset Management (USA) sold out of Ovid Therapeutics (OVID) in Q3 2017, closing a stake of 31,250 shares — an estimated $328K sold.

Lombard Odier Asset Management (USA) first reported a position in OVID in Q2 2017 and held it in 1 quarter. The position peaked at $328K in Q2 2017. 42 funds tracked by Wall St. Rank hold OVID as of Q3 2017.

  • Lombard Odier Asset Management (USA) reported no remaining Ovid Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 31,250 Ovid Therapeutics shares in Q3 2017, an estimated $328K.
  • Lombard Odier Asset Management (USA) first reported a position in Ovid Therapeutics in Q2 2017 and held it in 1 quarter.
  • Lombard Odier Asset Management (USA)'s Ovid Therapeutics position peaked at $328K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2017.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q3 2017, filed 14 Nov 2017.